Preventing The Evolution Of Transmissible Nitroimidazole Resistance In Mycobacterium Tuberculosis
Funder
National Health and Medical Research Council
Funding Amount
$664,463.00
Summary
Tuberculosis kills more people than any other infectious disease. Unfortunately, the drugs available to us to treat TB are losing their efficacy due to the evolution of drug resistance. A new class of drugs, nitroimidazoles, has been developed, but there is a risk that the bacterium that causes TB will develop resistance to these compounds too. We will identify resistance mutations before they occur in the wild, to help identify them and find new compounds for which resistance cannot develop.
Targeting Redox Homeostasis To Prevent Mycobacterium Tuberculosis Persistence
Funder
National Health and Medical Research Council
Funding Amount
$396,025.00
Summary
Tuberculosis is now the leading cause of death from infectious disease worldwide. This reflects the ability of its causative agent to persist, leading to failure of antibiotic treatment and development of drug resistance. In this project, we propose to overcome this by inhibiting a unique metabolic pathway that is activated when the pathogen enters its persistent state. We will use a cutting-edge combination of techniques to develop this pathway for next-generation therapies.